Oct 21 (Reuters) - Catalent president and CEO Alessandro Maselli said on Monday he will continue to lead the contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk .
Maselli's open letter comes on the back of increased criticism regarding Novo Holding's acquisition of Catalent that could threaten competition in weight-loss drugs and cutting-edge gene therapies.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
((Leroy.Dsouza@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。